BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Carb-X - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Carb-X
X-ORIGINAL-URL:https://carb-x.org
X-WR-CALDESC:Events for Carb-X
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210420
DTEND;VALUE=DATE:20210423
DTSTAMP:20260409T110612
CREATED:20201202T224742Z
LAST-MODIFIED:20210216T142945Z
UID:4658-1618876800-1619135999@carb-x.org
SUMMARY:Anti-Infectives Drug Development Summit
DESCRIPTION:Infectious diseases are one of the largest threats to global public health. The focus on the threat has never been greater\, with the COVID-19 pandemic demonstrating the critical need for a more proactive approach within governments\, biopharma\, and investment communities to overcome the pressing issues in anti-infective drug development to combat antimicrobial resistance. \nWith some now considering the field as the new ‘Wall Street darling’\, especially given the $1 billion launch of the AMR action fund\, the Digital Anti-Infectives Drug Development Summit has arrived as the most comprehensive and industry-dedicated forum that addresses the biggest challenges in the development and commercialization of anti-infective drugs. \nBringing together 60+ senior leaders from large pharma\, innovative biotech\, academia and investment companies\, join us this April to discuss data-driven and solution-based approaches that focus on developing high value clinical candidates\, novel modalities and effective strategies\, that address market sustainability and aim for superiority. \nCARB-X participants include Kevin Outterson\, Executive Director\, who will be leading the session “Surviving FDA Approval of your Antibiotic” on Wednesday April 21 at 9:25am ET / 6:25am PDT.  He will touch upon: \n\nWhat can we learn from the past decade of FDA antibiotic approvals? •\nNiche markets where your drug can differentiate from generics\nNon-dilutive funding: CARB-X\, BARDA\, HERA\nExit: AMR Action Fund\, PASTEUR\n\nCARB-X funded companies participating include Peptilogics\, Vedanta\, Antabio\, Bioversys\, ContraFect\, Locus\, Techulon\, Summit\, and MicuRx. \nClick here to learn more.\nClick here to view the event guide.\nClick here to register.
URL:https://carb-x.org/event/anti-infectives-drug-development-summit/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210420
DTEND;VALUE=DATE:20210423
DTSTAMP:20260409T110612
CREATED:20201203T004458Z
LAST-MODIFIED:20210323T185340Z
UID:4692-1618876800-1619135999@carb-x.org
SUMMARY:JPIAMR Therapeutics Workshop -  Feeding the Antimicrobial Pipeline
DESCRIPTION:As AMR emerges\, new strategies for the treatment of infection and identification of resistant microbes are crucial. This JPIAMR activity\, led by the UK Medical Research Council (MRC) with support from South Africa (SAMRC)\, Korea (NRF)\, France (ANR)\, and Canada (CIHR) is delivered as part of JPIAMR’s mission to enable global coordination of research. \nThe workshop “Feeding the AMR Therapeutics Pipeline” will bring together academics\, industry\, innovators\, and policymakers to discuss the global antimicrobial development pipeline\, identify gaps and opportunities for future research and development\, and support collaboration for creative solutions to real-world problems facing therapeutics development in the context of antimicrobial resistance (AMR). \nThe workshop is organised online in three half-day sessions\, (13:00-17:00 CET) from the 20th to the 22nd of April 2021\, combining keynote presentations\, short invited talks selected from abstract submissions\, and panel discussions. \nCARB-X participants include Kevin Outterson\, Executive Director\, who will be leading session “Session 2 Choosing wisely – is your product worth developing?” which will take place between 14:50 to 15:50 CET on April 20th.    \nClick here to learn more.\nClick here to register. \n 
URL:https://carb-x.org/event/jpiamr-therapeutics-workshop-april-2021/
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210420
DTEND;VALUE=DATE:20210423
DTSTAMP:20260409T110612
CREATED:20201221T211322Z
LAST-MODIFIED:20201221T211322Z
UID:4833-1618876800-1619135999@carb-x.org
SUMMARY:Anti-Infectives Drug Development Summit
DESCRIPTION:Infectious diseases are one of the largest threats to global public health. The focus on the threat has never been greater\, with the COVID-19 pandemic demonstrating the critical need for a more proactive approach within governments\, biopharma\, and investment communities to overcome the pressing issues in anti-infective drug development to combat antimicrobial resistance. \nWith some now considering the field as the new ‘Wall Street darling’\, especially given the $1 billion launch of the AMR action fund\, the Digital Anti-Infectives Drug Development Summit has arrived as the most comprehensive and industry-dedicated forum that addresses the biggest challenges in the development and commercialization of anti-infective drugs. \nBringing together 60+ senior leaders from large pharma\, innovative biotech\, academia and investment companies\, join us this April to discuss data-driven and solution-based approaches that focus on developing high value clinical candidates\, novel modalities and effective strategies\, that address market sustainability and aim for superiority. \nHere is a sneak peak of the world-class speaker faculty: \n\nCara Cassino\, Executive Vice President of R&D & Chief Medical Officer\, ContraFect\nKevin Outterson\, Executive Director\, CARB-X\nSilas Holland\, Head of External Affairs (Interim) & Director of Global Policy\, Merck & The AMR Action Fund\nDavid Powell\, Chief Scientific Officer\, Summit Therapeutics\nDave Ousterout\, Chief Scientific Officer\, Locus Biosciences\nAngela Talley\, Vice President of Clinical Development\, Spero Therapeutics\nErcem Atillasoy\, Chief Regulatory & Safety Officer\, AlloVir\nDavid Alterac\, Chief Medical Officer\, Entasis Therapeutics\n\nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/anti-infectives-drug-development-summit-2/
LOCATION:Virtual Event\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
END:VCALENDAR